重建皮肤模型市场 - 类型（重建人类表皮、重建人类皮肤）、应用（皮肤刺激、腐蚀、致敏、活检、放射性过敏吸附剂和色素沉着测试）、最终用户、全球预测（2024 - 2032）

在个人化医疗需求不断增长和技术快速进步的推动下，2024年至2032年全球重建皮肤模型市场规模的复合年增长率将达到14.6%。随着医疗保健向个人化治疗过渡，重建皮肤模型为安全性和功效测试提供了量身定制的方法，同时满足了精准医疗的需求。

此外，组织工程和生物技术的不断进步正在增强这些模型的精确度和可靠性，使它们对于製药、化妆品和生物技术领域追求日益预测和道德的测试方法不可或缺。例如，2023 年 7 月，欧莱雅与加州大学柏克莱分校贝克实验室合作，为精选新创公司提供其 3D 重建皮肤模型的存取权限。此次合作为创新公司提供了免费使用欧莱雅先进的非动物测试解决方案以进行安全性和功效测试的机会。

重建皮肤模型市场根据类型、应用、最终用户和地区进行细分。

按类型划分，到 2032 年，重建人体皮肤细分市场将占据相当大的行业份额，因为它与天然人体皮肤非常相似，可以为安全性和功效测试提供高度准确和可靠的结果。组织工程方法的进步促进了复杂重建的人体皮肤模型的创建，这些模型密切复製了天然皮肤的复杂结构和功能。

根据应用情况，由于人们对化学暴露的不利影响的认识不断提高以及对准确和道德测试方法的需求，到 2032 年，皮肤致敏测试领域的重建皮肤模型行业将出现显着增长。重建的皮肤模型为评估皮肤致敏潜力提供了可靠的平台，无需进行动物测试。随着监管压力提倡替代测试方法和行业优先考虑安全性，对采用重建皮肤模型的皮肤过敏测试的需求将会增加。

由于先进的医疗基础设施、广泛的 RampD 活动和严格的监管框架，北美重建皮肤模型产业规模将在 2024 年至 2032 年呈现显着的复合年增长率。此外，主要市场参与者的存在正在增加对生物技术和製药行业的投资。随着对道德测试方法和安全法规的日益重视，北美将脱颖而出，成为市场成长的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 越来越多地采用动物测试的替代测试程序
    • 皮肤病盛行率增加
    • 日益关注精准化妆品
    • 不断增加对先进体外模型开发的投资
  • 产业陷阱与挑战
    • 与不同批次的再现性相关的问题
    • 存在严格的监管审批流程
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 重建人类表皮
• 重建人体皮肤

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 皮肤刺激测试
• 皮肤腐蚀测试
• 皮肤致敏试验
• 皮肤切片
• 放射性过敏吸附剂测试
• 皮肤色素沉淀测试
• 其他应用

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 化妆品和药妆公司
• 化工企业
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AIVITA Biomedical, Inc.
• BICO - THE BIO CONVERGENCE COMPANY
• CELLnTEC
• EPISKIN
• Henkel AG & Co. KGaA
• Japan Tissue Engineering Co., Ltd.
• Mallinckrodt plc
• STRATICELL
• WEPREDIC Group (Biopredic International)
• ZenBio, Inc.

Global Reconstructed Skin Models Market size will record 14.6% CAGR from 2024 to 2032, driven by the increasing demand for personalized medicine and rapid advancements in technology. As healthcare transitions towards individualized treatments, reconstructed skin models offer a tailored approach for safety and efficacy testing while aligning with the need for precision medicine.

Moreover, the ongoing advancements in tissue engineering and biotechnology are bolstering the precision and dependability of these models, making them indispensable for the pharmaceutical, cosmetic, and biotechnology sectors in pursuit of the increasingly predictive and ethical testing methodologies. For instance, in July 2023, LOreal partnered with UC Berkeley's Baker Labs for offering select start-ups access to its 3D reconstructed skin models. This collaboration provided innovative companies with free access to LOreals advanced non-animal testing solutions for safety and efficacy testing.

The reconstructed skin models market is segmented on the basis of type, application, end-user, and region.

By type, the reconstructed human skin segment will capture considerable industry share by 2032, owing to its close resemblance to natural human skin for providing highly accurate and reliable results for safety and efficacy testing. The progress in tissue engineering methodologies has facilitated the creation of intricately reconstructed human skin models that closely replicate the intricate structure and functions of natural skin.

Based on application, the reconstructed skin models industry from the skin sensitization test segment will witness significant growth by 2032 due to rising awareness regarding the adverse effects of chemical exposure and the need for accurate and ethical testing methods. Reconstructed skin models offer a reliable platform for assessing skin sensitization potential without the need for animal testing. With regulatory pressures advocating alternative testing methods and industries prioritizing safety, the demand for skin sensitization tests employing reconstructed skin models will rise.

North America reconstructed skin models industry size will demonstrate a remarkable CAGR from 2024 to 2032, attributed to the advanced healthcare infrastructure, extensive R&D activities, and stringent regulatory frameworks. Additionally, the presence of key market players is increasing the investments in biotechnology and pharmaceutical sectors. With the growing emphasis on ethical testing methods and safety regulations, North America will stand out as a significant contributor to the market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising adoption of alternative testing procedures to animal testing
    • 3.2.1.2 Increasing prevalence of skin disorders
    • 3.2.1.3 Growing focus on precision cosmetic products
    • 3.2.1.4 Growing investments in the development of advanced in-vitro models
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Concerns related to reproducibility across different batches
    • 3.2.2.2 Presence of stringent regulatory approval process
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Reconstructed human epidermis
• 5.3 Reconstructed human skin

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Skin irritation test
• 6.3 Skin corrosion test
• 6.4 Skin sensitization test
• 6.5 Skin biopsy
• 6.6 Radioallergosorbent test
• 6.7 Skin pigmentation test
• 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cosmetics and cosmeceutical companies
• 7.3 Chemical companies
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AIVITA Biomedical, Inc.
• 9.2 BICO - THE BIO CONVERGENCE COMPANY
• 9.3 CELLnTEC
• 9.4 EPISKIN
• 9.5 Henkel AG & Co. KGaA
• 9.6 Japan Tissue Engineering Co., Ltd.
• 9.7 Mallinckrodt plc
• 9.8 STRATICELL
• 9.9 WEPREDIC Group (Biopredic International)
• 9.10 ZenBio, Inc.